Dilator reserve of the coronary microvasculature is diminished in patients with dilated cardiomyopathy. Although increased extravascular compressive forces, tachycardia, and increased myocardial mass can explain some impairment, recent evidence suggests the possibility of intrinsic microvascular disease. We tested the hypothesis that impairment of endothelium-dependent dilation of the microvasculature could be a contributing mechanism. We infused the endothelium-dependent dilator acetylcholine (Ach) (10-8 to 10-6 M) and the smooth muscle vasodilator adenosine (AD) (10-6 to 10`-M) into the left anterior descending coronary artery in eight patients with dilated cardiomyopathy (mean ejection fraction, 28%) and seven controls (atypical chest pain). Small In seven control patients receiving both Ach and AD, 56±9%o of the maximal AD flow response was attained with the endothelium-dependent vasodilator Ach, whereas in seven cardiomyopathy patients receiving both Ach and AD, only 23±14% of the maximal AD response was attained (p<0.01). Thus, endothelium-dependent vasodilator function is impaired in the coronary microvasculature of patients with dilated cardiomyopathy. There might be pathogenetic links between dysfunction of the endothelium and myocardial failure. (Circulation 1990;81:772-779) C oronary flow reserve is diminished in patients with dilated cardiomyopathy (DC).1-5 Elevated filling pressures, increased heart rate, decreased coronary perfusion pressure, and increasing left ventricular mass out of proportion to micro-
Dilator reserve of the coronary microvasculature is diminished in patients with dilated cardiomyopathy. Although increased extravascular compressive forces, tachycardia, and increased myocardial mass can explain some impairment, recent evidence suggests the possibility of intrinsic microvascular disease. We tested the hypothesis that impairment of endothelium-dependent dilation of the microvasculature could be a contributing mechanism. We infused the endothelium-dependent dilator acetylcholine (Ach) (10-8 to 10-6 M) and the smooth muscle vasodilator adenosine (AD) (10-6 to 10`-M) into the left anterior descending coronary artery in eight patients with dilated cardiomyopathy (mean ejection fraction, 28%) and seven controls (atypical chest pain). Small vessel resistance was assessed by measuring coronary blood flow (CBF) at constant arterial pressure with a Doppler velocity catheter (corrected for cross-sectional area by angiography). With Ach, control patients increased CBF 232+40%1 (mean+SEM), whereas CBF did not significantly change in cardiomyopathy patients (41+24%) (p<0.0001, control vs. cardiomyopathy). With AD, control patients increased CBF 422+±56% and cardiomyopathy patients increased CBF 268+±43% (p=0. 13 ). An index of the proportion of coronary flow reserve attributable to endothelium-dependent vasodilation was obtained by standardizing each patient's Ach dose response to his maximal AD flow response. In seven control patients receiving both Ach and AD, 56±9%o of the maximal AD flow response was attained with the endothelium-dependent vasodilator Ach, whereas in seven cardiomyopathy patients receiving both Ach and AD, only 23±14% of the maximal AD response was attained (p<0.01). Thus, endothelium-dependent vasodilator function is impaired in the coronary microvasculature of patients with dilated cardiomyopathy. There might be pathogenetic links between dysfunction of the endothelium and myocardial failure. (Circulation 1990; 81:772-779) C oronary flow reserve is diminished in patients with dilated cardiomyopathy (DC).1-5 Elevated filling pressures, increased heart rate, decreased coronary perfusion pressure, and increasing left ventricular mass out of proportion to micro-effectively prevented microvascular spasm and averted the development of cardiomyopathy,1" suggesting an etiologic role of the microvasculature in this disease.
The vascular endothelium has been recognized as playing a pivotal role in maintaining vascular tone through the release of endothelium-derived relaxing factor(s) (EDRF). EDRF-mediated vasodilation is seen in both large and small coronary vessels in response to a variety of agents including acetylcholine.14-'7 Loss of normal endothelial function in atherosclerosis, Kawasaki's, and other diseases might predispose the patient to vasospasm.15 '18-21 The goals of this study were to determine whether endothelium-dependent vasodilator function is abnormal in DC and whether this abnormality could contribute to the disturbed coronary flow regulation found in this disease.
Methods

Patient Population
Eight patients with DC (defined as markedly impaired left ventricular systolic function with no epicardial atherosclerotic coronary artery disease detectable by angiography) and seven normal controls (atypical chest pain) undergoing diagnostic catheterization were studied. All patients had angiographically normal coronary arteries. Patients with valvular heart disease, hypertrophic cardiomyopathy, hypertensive heart disease, congenital heart disease, evidence of restrictive or constrictive physiology, or uncontrolled heart failure ( Serial 2-minute intracoronary infusions of acetylcholine and adenosine were administered at 0.8 ml/min through the central lumen of the Doppler catheter in the following sequence: control (5% dextrose with heparin 1 unit/ml); graded concentrations of acetylcholine (to achieve estimated final blood concentrations of 10-8, 10-7, and 10-6 M based on assumed LAD blood flow of 80 ml/min in normal subjects23 and in patients with DC24), repeat control (0.9% sodium chloride), and graded concentrations of adenosine (Sigma Chemical Co., St. Louis, Missouri) (to achieve estimated final blood concentrations of 10-6, 10-5, and 10-4 M assuming resting blood flow in the LAD of 80 ml/min). With the increase in blood flow observed at higher doses, the actual concentrations were proportionately lower. Just before the end of each infusion, coronary arteriography was performed in biplane orthogonal views with the use of a power injection of nonionic contrast medium (Omnipaque, Winthrop-Breon, New York). Throughout each infusion, the heart rate, arterial pressure, coronary flow velocity, and electrocardiogram (lead I) were monitored continuously, and all measurements were recorded in steady-state conditions.
Quantitative coronary angiography. Quantitative coronary angiography was performed by a previously validated technique.25 Nonionic contrast medium was injected into the left coronary artery at the rate of 5-10 ml/sec to a total of 7-12 ml with the use of a power injector (Medrad, Pittsburgh, Pennsylvania) to optimize the quality and reproducibility of the injections.26 A biplane system (Polydiagnost-C, Philips Medical Systems, Inc., Shelton, Connecticut) with two image intensifiers was used, and the LAD was positioned in the center of each field of view and at a single position in space (isocenter).
Analysis ofarterial dimensions. Quantitative angiography of the epicardial coronary artery was performed for two reasons. The first purpose was to determine cross-sectional area near the Doppler tip to convert flow velocity to an estimate of coronary arterial flow. (As shown in Figure 1 , an arterial segment 2-4 mm distal to the Doppler tip was selected for quantitative analysis in all patients.) The second purpose was to exclude limitations of coronary artery flow due to epicardial coronary artery constriction in response to acetylcholine (flow limitation defined as >50% diameter constriction in the most constricting segment). Quantitative angiographic analysis was similar to that described in previous studies. 27 The four digitized cine frames for each infusion were summed and averaged along the segment profile to give a mean diameter and standard deviation at each point. A single mean and a pooled standard deviation for the segment (at each infusion) were obtained by averaging each of these measurements along the segment profile. Suitable segments were required to have a mean standard deviation less than 5% of the mean diameter.
Estimates of coronary blood flow changes. Estimates of relative changes in coronary blood flow were made by correcting changes in mean coronary blood flow velocity, as measured directly by the Doppler catheter, for changes from control in estimated vessel cross-sectional area at the catheter tip as determined from the change in diameter measured in the optimal single plane view.
Statistical Analysis
Differences in dose-response curves to serial doses of acetylcholine and adenosine were evaluated among groups by analysis of covariance for repeated measures. Differences in individual doses from baseline were evaluated with one-sample t tests. Differences in hemodynamic and echocardiographic parameters were analyzed by Wilcoxon rank sum tests. Statistical significance was assumed if the null hypothesis (two-tailed) could be rejected at the 0.05 probability level. All data are expressed as the mean+SEM. Results 
Baseline Clinical and Hemodynamic Characteristics
Patients with DC were 46±7 years old (range, 19-68 years); all were male (Table 1) . One DC patient had a significant history of alcohol ingestion (1.4 quarts of brandy per day for 20 years), and two DC patients had a history of alcohol use in quantities reported to be inadequate to cause myocardial dysfunction28 (six beers per night for 15 years and four beers per night for 10 years). Two DC patients had a family history of DC.
Six of eight DC patients underwent endomyocardial biopsy. Marked myocyte hypertrophy and fibrosis were present on all six specimens. No patient had active myocarditis on biopsy.
Control patients (C) were 40±2 years old (range, 31-48 years). One was female ( Infusion of adenosine over the range of 10`6 to 10`M into the LAD coronary artery produced a dose-dependent increase in estimated coronary blood flow in DC and C patients (Figure 3 ). Estimated blood flow increased 113±19% with 10-6, 180±24% with 10-5, and 268±43% with 10-4 M adenosine in DC patients (all, p<0.05 vs. baseline value) and 163±45% with 10-6, 292±47% with 10-5, and 424±56% with 10`M adenosine in C patients (all, p<0.05 vs. baseline value). No significant difference between the dose-response curves to adenosine in C (slope, 134) and DC (slope, 70) patients was demonstrated by analysis of covariance for repeated measures (p=0.13).
To examine the endothelium-dependent component of vasodilation, the increase in flow to acetylcholine in each patient was standardized to his/her own maximal flow response to adenosine. These data (Figure 4) show that the acetylcholine response (endothelium-dependent), standardized to the maximal response to adenosine (endothelium-independent), was deficient in the DC patients. The standardized dose-response curve to acetylcholine in the seven DC patients who received both acetylcholine and adenosine (slope, 0.07) was significantly lower than the standardized dose-response curve to acetylcholine in the seven C patients who received both acetylcholine and adenosine (slope, 0.23) (p<0.01, by analysis of covariance for repeated measures). Discussion This study demonstrates impaired relaxation of the microvasculature in patients with DC in response to the endothelium-dependent vasodilator acetylcholine. This impairment is out of proportion to the mildly impaired response to adenosine, a dilator of vascular smooth muscle. The loss of relaxation to acetylcholine with a relatively intact relaxation response to adenosine suggests that extravascular factors do not explain the pronounced differences in acetylcholine responses between normal and cardiomyopathic patients and suggests a role for endothelial dysfunction in the microvasculature of hearts with DC.
Coronary flow reserve has been shown to be diminished in patients with DC. Horwitz et all first reported impaired coronary blood flow responses to the intravenous administration of isoproterenol in heart failure. Subsequently, studies using the thermodilution method of measuring coronary sinus blood flow3'5 and the argon washout method4 demonstrated impaired dilator capacity during rapid atrial pacing5 and after dipyridamole.3,4 Intracoronary administration of adenosine in our patients also demonstrated a trend toward impairment of coronary flow reserve in patients with DC. The present study, however, is the first to be able to differentiate the role of intrinsic microvascular disease from other extravascular factors that can alter coronary flow reserve.
Although studies of microvascular pathology in hypertrophic cardiomyopathy have demonstrated intimal hyperplasia and medial hypertrophy,6,7 most studies of the microvasculature in DC have failed to demonstrate any morphological abnormalities. Evidence from experimental models of DC as well as recent clinical studies, however, have convincingly documented disturbances in microvascular function. Factor10-12 and others13 have described microvascular spasm as a preventable cause of hereditary DC in the Syrian hamster. Silicone rubber-perfusion studies demonstrated microvascular spasm associated with adjacent areas of myocytolytic necrosis early in this disease. Administration of the calcium channel blocker verapamil, an agent effective in the treatment of vasospasm, halted the progression of myocardial necrosis and prevented the development of cardiomyopathy.1" Cannon et a18 studied 12 patients with DC, normal epicardial coronary arteries, and a history of chest pain, and found that 11 developed anginal symptoms with ergonovine administration. The apparent increased sensitivity to the vasoconstrictor stimulus ergonovine suggests an intrinsic functional abnormality of the coronary microvasculature.
The endothelium is fundamentally important in the local regulation of vascular tone. The release of EDRF is the mode of action for a variety of vasodilators including acetylcholine, adenosine diphosphate (ADP), adenosine triphosphate (ATP), histamine, bradykinin, substance P, thrombin, and calcitonin gene-related peptide.14 Even substances that are normally considered to be vasoconstrictors, such as a-adrenergic receptor agonists, vasopressin, and serotonin, can release EDRF. 29, 30 Diseases, such as atherosclerosis, which are associated with impaired endothelium-dependent relaxation, can lead to an imbalance between vasoconstrictor and vasodilator influences and result in vasospasm in the epicardial coronary arteries. 1'518 Although the majority of early studies of endothelial modulation of vascular tone have involved the large (conduit) arteries, there is convincing evidence that endothelium-mediated vasomotion also plays an important role in the control of the small (resistance) vessels.16 '17,31 For example, in the perfused mesenteric arterial vasculature of the rabbit, vasodilation by acetylcholine was almost completely blocked after the removal of endothelial cells with collagenase.17 In the rat microvasculature, vasodilation by acetylcholine was markedly inhibited by hemoglobin, an agent that inactivates EDRF. 31 The present study has shown that normal humans exhibit cholinergically mediated dose-dependent dilation of the coronary microvasculature, a function that is likely to be endothelium dependent.
A dysfunctional endothelium could contribute to the development or progression of cardiomyopathy by one of two mechanisms. In analogy to reports regarding hereditary cardiomyopathy in the Syrian hamster,10-13 microvascular spasm, triggered by impaired endothelium-dependent vasodilation, could impair the nutritive support of myocardium, interfere with its contractile function, and possibly induce focal areas of myocardial necrosis. Alternatively, impaired relaxation to acetylcholine could represent only one of a number of endothelial functions that are abnormal in this disease. Normal endothelium can provide trophic support to the surrounding tissues by producing a variety of growth factors such as platelet-derived growth factor,32,33 fibroblast growth factor,34 and insulin-like growth factor.35 Deranged regulation of the production or release of these growth factors or other trophic substances could be a pathogenic feature of cardiomyopathies.
The cause or causes of endothelial dysfunction in the coronary microvessels of DC hearts demonstrated in this study remain to be defined. It is possible that the endothelium is secondarily damaged in heart failure. Abnormal endothelium-mediated vascular regulation could lead to further damage in later stages of the disease. This concept is supported by the observations of Kaiser and colleagues36 who found impaired endothelium-dependent vasodilation to acetylcholine in the hindlimb of dogs with experimental heart failure. Alternatively, endothelial dysfunction could represent an early primary defect. The two most impaired responses to acetylcholine in this study were observed in patients with a family history of DC. Possibly, a genetic defect could affect the endothelium primarily. There are also external stimuli that have been associated with the development of cardiomyopathies and that damage endothelial cells directly. For example, various viruses invade and destroy endothelial cells,37-40 and ethanol exposure produces injury to microvascular endothelial cells.41 Epicardial (conduit) arteries of cardiomyopathy and control patients did not differ significantly in their responses to acetylcholine or adenosine, suggesting that the impairment in endothelium-dependent relaxation affecting the heart might primarily involve the microvasculature.
One must also consider mechanisms other than dysfunction of endothelium that might explain the data presented in this study. A 
